At the time of writing, Summit Therapeutics Inc [SMMT] stock is trading at $18.82, up 3.63%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 5.46% over the last week, with a monthly amount glided 1.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on January 08, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $35. Previously, Wells Fargo started tracking the stock with Overweight rating on December 11, 2024, and set its price target to $30. On December 06, 2024, Jefferies initiated with a Buy rating and assigned a price target of $31 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $32 on November 04, 2024. Citigroup downgraded its rating to a Neutral and raised its price target to $23 on September 27, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on August 12, 2024, and assigned it a price target of $16. In a note dated May 07, 2024, Citigroup initiated an Buy rating and provided a target price of $7 on this stock.
For the past year, the stock price of Summit Therapeutics Inc fluctuated between $2.10 and $33.89. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $18.82 at the most recent close of the market. An investor can expect a potential return of 85.97% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
Gross Profit Margin for this corporation currently stands at 3.86% with Operating Profit Margin at 772.26%, Pretax Profit Margin comes in at 837.61%, and Net Profit Margin reading is 836.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -1.04 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.15 points at the first support level, and at 17.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.44, and for the 2nd resistance point, it is at 20.06.
Ratios To Look Out For
It is important to note that Summit Therapeutics Inc [NASDAQ:SMMT] has a current ratio of 8.31. As well, the Quick Ratio is 8.31, while the Cash Ratio is 1.59.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
